The top 3 wholesalers, representing around 85% of the market, are AmeriSourceBergen, Cardinal Health and McKesson. Restoring Social Trust in Democracy, Democracy, Government Reform, Senior Director of the Trump Administration, Security and Justice Campaign and Director, State and Local Government Affairs Although the Trump administration continues to promise to lower drug prices, drug costs continue increasing as Americans suffer pharmaceutical companies benefit and their CEOs line their pockets. Government-funded research and the significant tax benefits enjoyed by these pharmaceutical companies help them stay profitable. Meanwhile, drug costs continue to rise, particularly life-sustaining drugs, such as insulin.
While Americans are caught trying to decide whether to pay rent or drugs, pharmaceutical companies continue to reap government benefits. Reducing drug prices and the costs ordinary people must pay is not possible without fixing Washington's broken system. Abbey Meller is an organizing associate of Democracy and Government at the Center for American Progress. Hauwa Ahmed is a research assistant for Democracy and Government at the Center.
The positions of American Progress, and of our policy experts, are independent, and the findings and conclusions presented are only those of American Progress. The full list of supporters is available here. American Progress would like to thank the many generous supporters who make our work possible. Jawando, Igor Volsky, Sally Tucker, 1 More Rachel Rosen, Jared C.
Bass, Jesse O'Connell The Center for American Progress is an independent, nonpartisan policy institute dedicated to improving the lives of all Americans through bold and progressive ideas, as well as strong leadership and concerted action. Our goal is not just to change the conversation, but to change the country. Meet our sister organization, the Center for American Progress Action Fund, an advocacy organization dedicated to improving the lives of all Americans. In some cases, it was not possible to isolate the results of pharmaceutical business activities, for example, health insurers do not report the financial results of their pharmaceutical claims activity separately from the medical claims activity.
While consumers continue to pay the price for this market manipulation, a Government Accountability Office (GAO) report on the pharmaceutical industry found that these unfair practices are significantly enriching manufacturers. While specialty drugs represent a small share of the drug market by volume, they account for a large part of pharmaceutical spending. While considerable efforts and expenses have been invested to innovate, develop and market medicines more efficiently, only minimal effort has been made to reconfigure manufacturing and distribution operations or adjust the pharmaceutical supply chain network. In the meantime, the FDA should convene a working group of stakeholders, including the International Federation of Pharmaceutical Manufacturers and Associations and the Generic Pharmacists Association, to promote voluntary tracking and tracing of all actors in the supply chain in accordance with existing guidelines.
To the same end, governments, the World Health Organization and the International Pharmaceutical Federation should support national pharmacy councils and education departments to train pharmaceutical staffing levels.